Biological subtypes and survival outcomes in breast cancer patients with brain metastases (study of the anatolian society of medical oncology)

Oncology (Switzerland)

Volumn 83, Issue 3, 2012, Pages 141-150

  Kaplan, Muhammet Ali ^a,o   Isikdogan, Abdurrahman ^a   Koca, Doǧan ^b   Kucukoner, Mehmet ^a   Gumusay, Ozge ^c   Yildiz, Ramazan ^d   Dayan, Adem ^b   Demir, Ltfiye ^f   Geredeli, Caglayan ^g   Kocer, Murat ^h   Arslan, Ulku Yalcintas ^e   Nal, Ali ^a   Unal, Olcun Umit ^b   Mert, Aslhan Guven ^d   Bilici, Mehmet ⁱ   Ozkan, Metin ^j   Elkiran, Emin Tamer ⁿ   Yaman, Sebnem ^m   Durnal, Ayse Gok ^e   Suner, Ali ^k   Alici, Suleyman ^l   Tarhan, Mustafa Oktay ^f   Boruban, Cem ^g   Urakci, Zuhat ^a   Buyukberber, Suleyman ^c   more..

^a DICLE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b DOKUZ EYLUL UNIVERSITY   (Turkey)

^c GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^d Dr Lutfi Krdar Kartal Training and Research Hospital   (Turkey)

^e ANKARA ONCOLOGY EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^f ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

^g SELCUK UNIVERSITY   (Turkey)

^h SULEYMAN DEMIREL UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

ⁱ ATATURK UNIVERSITY   (Turkey)

^j ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

^k GAZIANTEP UNIVERSITY   (Turkey)

^l MEDICAL PARK HOSPITAL   (Turkey)

^m ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

ⁿ INONU UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^o DICLE UNIVERSITY   (Turkey)

more..

Author keywords

Biological subtype; Brain metastasis; Breast cancer

Indexed keywords

ANTHRACYCLINE; AROMATASE INHIBITOR; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; FULVESTRANT; GEMCITABINE; GOSERELIN; HORMONE RECEPTOR; LAPATINIB; NAVELBINE; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY; CLINICAL STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; FEMALE; HUMAN; LUMINAL A BREAST CANCER; LUMINAL B BREAST CANCER; MAJOR CLINICAL STUDY; NEUROSURGERY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RADIOSURGERY; RETROSPECTIVE STUDY; TRIPLE NEGATIVE BREAST CANCER; TURKEY (REPUBLIC);

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; QUINAZOLINES; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SURVIVAL RATE; TAMOXIFEN; TURKEY;

EID: 84863858493     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000338782     Document Type: Article

References (36)

1. Patchell RA: The management of brain metastases. Cancer Treat Rev 2003;29:533-540. (Pubitemid 37428325)
2. Lin NU, Bellon JR, Winer EP: CNS metastases in breast cancer. J Clin Oncol 2004;22:3608-3617. (Pubitemid 41103668)
3. Boogerd W: Central nervous system metastasis in breast cancer. Radiother Oncol 1996;40:5-22. (Pubitemid 26246261)
4. Kim HJ, Im SA, Keam B, Kim YJ, Han SW, Kim TM, et al: Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment. J Neurooncol 2012;106:303-313.
5. Leyland-Jones B: Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J Clin Oncol 2009;27:5278-5286.
6. Soffietti R, Ruda R, Trevisan E: Brain metastases: current management and new developments. Curr Opin Oncol 2008;20:676-684.
7. Hagemeister FB Jr, Buzdar AU, Luna MA, Blumenschein GR: Causes of death in breast cancer: a clinicopathologic study. Cancer 1980;46:162-167. (Pubitemid 10080453)
8. Boogerd W, Dalesio O, Bais EM, van der Sande JJ: Response of brain metastases from breast cancer to systemic chemotherapy. Cancer 1992;69:972-980.
9. Arnold SM, Patchell RA: Diagnosis and management of brain metastases. Hematol Oncol Clin North Am 2001;15:1085-1107. (Pubitemid 33131200)
10. van Vulpen M, Kal HB, Taphoorn MJ, El-Sharouni SY: Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? Oncol Rep 2002;9:683-688.
11. Norden AD, Wen PY, Kesari S: Brain metastases. Curr Opin Neurol 2005;18:654-661. (Pubitemid 41669138)
12. Arslan UY, Oksuzoglu B, Aksoy S, Harputluoglu H, Turker I, Ozisik Y, et al: Breast cancer subtypes and outcomes of central nervous system metastases. Breast 2011;20:562-567.
13. Niwiñska A, Murawska M, Pogoda K: Breast cancer subtypes and response to systemic treatment after whole-brain radiotherapy in patients with brain metastases. Cancer 2010;116:4238-4247.
14. Niwiñska A, Murawska M, Pogoda K: Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Ann Oncol 2010;21:942-948.
15. Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN: Is breast cancer survival improving? Cancer 2004;100:44-52.
16. Metro G, Foglietta J, Russillo M, Stocchi L, Vidiri A, Giannarelli D, et al: Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Ann Oncol 2011;22:625-630.
17. Bartsch R, Berghoff A, Pluschnig U, Bago-Horvath Z, Dubsky P, Rottenfusser A, et al: Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases. Br J Cancer 2012;106:25-31.
18. Fabi A, Vidiri A, Ferretti G, Felici A, Papaldo P, Carlini P, et al: Dramatic regression of multiple brain metastases from breast cancer with capecitabine: another arrow at the bow? Cancer Invest 2006;24:466-468. (Pubitemid 43932692)
19. Ekenel M, Hormigo AM, Peak S, Deangelis LM, Abrey LE: Capecitabine therapy of central nervous system metastases from breast cancer. J Neurooncol 2007;85:223-227. (Pubitemid 47629405)
20. Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N: Triplenegative breast cancer - current status and future directions. Ann Oncol 2009;20:1913-1927.
21. Arslan C, Dizdar O, Altundag K: Pharmacotherapy of triple-negative breast cancer. Expert Opin Pharmacother 2009;10:2081-2093.
22. Aksoy S, Dizdar O, Harputluoglu H, Altundag K: Demographic, clinical, and pathological characteristics of Turkish triple-negative breast cancer patients: single center experience. Ann Oncol 2007;18:1904-1906. (Pubitemid 350111578)
23. Nam BH, Kim SY, Han HS, Kwon Y, Lee KS, Kim TH, Ro J: Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res 2008;10:R20.
24. Eichler AF, Kuter I, Ryan P, Schapira L, Younger J, Henson JW: Survival in patients with brain metastases from breast cancer: the importance of HER-2 status. Cancer 2008;112:2359-2367.
25. Dawood S, Broglio K, Esteva FJ, Ibrahim NK, Kau SW, Islam R, et al: Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol 2008;19:1242-1248. (Pubitemid 351911952)
26. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182. (Pubitemid 17231334)
27. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792. (Pubitemid 32222155)
28. Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, et al: Clinical activity of trastuzumab and vinorelbin in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001;19:2722-2730. (Pubitemid 32441378)
29. Pestalozzi BC, Brignoli S: Trastuzumab in CSF. J Clin Oncol 2000;18:2349-2351.
30. Bartsch R, Rottenfusser A, Wenzel C, Dieckmann K, Pluschnig U, Altorjai G, et al: Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer. J Neurooncol 2007;85:311-317. (Pubitemid 350142522)
31. Eichler AF, Kuter I, Ryan P, Schapira L, Younger J, Henson JW: Survival in patients with brain metastases from breast cancer: the importance of HER-2 status. Cancer 2008;112:2359-2367.
32. Lin NU, Diéras V, Paul D, Lossignol D, Christodoulou C, Stemmler HJ, et al: Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009;15:1452-1459.
33. Gril B, Palmieri D, Bronder JL, Herring JM, Vega-Valle E, Feigenbaum L, et al: Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst 2008;100:1092-1103.
34. Sutherland S, Ashley S, Miles D, Chan S, Wardley A, Davidson N, et al: Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases - the UK experience. Br J Cancer 2010;102:995-1002.
35. Dawood S, Broglio K, Esteva FJ, Yang W, Kau SW, Islam R, et al: Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol 2009;20:621-627.
36. Kirsch DG, Ledezma CJ, Mathews CS, Bhan AK, Ancukiewicz M, Hochberg FH, et al: Survival after brain metastases from breast cancer in the trastuzumab era. J Clin Oncol 2005;23:2114-2116; author reply 2116-2117 (Pubitemid 46211402)